FCAAIA Notes: In pediatrics, most medications re dosed by weight. Now, there is an auto-injectable epinephrine dosed for infants and toddlers. However, if you have a baby and have a 0.15 mg auto-injector, I would not discard it. First of all, Continue reading “FDA OKS EPINEPHRINE AUTO-INJECTOR FOR SMALL CHILDREN”
FCAAIA Notes: Until now, I have only posted articles about a specific brand of a medication if it is the only one available in its class. However, the absence of Auvi-Q has been a real problem from many patients, especially because the manufacturers of its competitor (EpiPen by Mylan) raised its price prohibitively high. Continue reading “AUVI-Q RETURNING TO MARKET IN 2017”
FCAAIA Notes: Epinephrine (adrenalin) is the treatment of choice for anaphylaxis. Delay in administration of epinephrine is the major risk factor for poor outcomes in anaphylaxis, including anaphylactic death.
Patients at risk for anaphylaxis should own an epinephrine auto-injector (e.g., EpiPen) and know how to use it. Continue reading “ANAPHYLAXIS: EARLY EPINEPHRINE TIED TO FEWER OVERALL DOSES”
FCAAIA Notes: Most episodes of anaphylaxis are “uniphasic” meaning that when treated symptoms resolve fairly quickly and do not recur afterwards. Nonetheless, 3-20% of anaphylaxis is biphasic. That is, symptoms completely resolve over a few hours with treatment but then recur 4-8 hours later, often with the same severity. This study confirms previous data and observation that more severe episodes, those requiring more than one dose of epinephrine, and a delay in treatment are associated with an increased risk of biphasic reactions. Earlier studies indicated a higher rate in adults, but this study indicates a higher rate in early school aged children, a finding that needs to be confirmed.
Anaphylaxis should be treated first with epinephrine Continue reading “RESEARCHERS IDENTIFY PREDICTORS OF DELAYED ALLERGIC REACTIONS IN CHILDREN”